The Chemotherapy Induced Anemia Market is Expected to Show Positive Growth in the 7MM During the Study Period (2019-32)
The Chemotherapy Induced Anemia market is expected to grow owing to the disease awareness and the emergence of new products in the pipeline. In addition, persistently rising cases of Chemotherapy Induced Anemia in the forecast period will help increase the Chemotherapy Induced Anemia market size.
LAS VEGAS , April 6, 2022 /PRNewswire/ -- DelveInsight's Chemotherapy Induced Anemia Market Insights report provides a comprehensive understanding of current treatment practices, Chemotherapy Induced Anemia emerging drugs, market share of individual therapies, and current and forecasted Chemotherapy Induced Anemia market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan.
Key Takeaways from the Chemotherapy Induced Anemia Market
- As per DelveInsight's estimates, the Chemotherapy Induced Anemia market size was USD 1,061.9 million in 2021 which is further expected to increase by 2032 in the 7MM.
- Among the 7MM, the US accounted for the maximum Chemotherapy Induced Anemia market size in 2021.
- Key Chemotherapy Induced Anemia companies such as Astellas, FibroGen, AstraZeneca, Aileron Therapeutics, Zydus Cadila, and others are working proactively in the Chemotherapy Induced Anemia market.
- The Chemotherapy Induced Anemia drugs in the pipeline include Roxadustat (FG-4592), ALRN-6924, Desidustat, and others.
- The increase in the number of Chemotherapy Induced Anemia cases is likely to contribute directly to the market growth during the forecast period.
For further information on how the emerging therapies would shift the Chemotherapy Induced Anemia market landscape download the sample @ Chemotherapy Induced Anemia Market Outlook
Chemotherapy Induced Anemia Overview
Chemotherapy Induced Anemia is caused by malignant invasion of normal tissue, which results in blood loss, bone marrow infiltration with disruption of erythropoiesis, and functional iron deficiency as a result of inflammation. The pathogenesis of Chemotherapy Induced Anemia is complex and frequently difficult to identify, and it is usually multifactorial.
Anemia can cause a wide range of symptoms in cancer patients, affecting almost every organ. The severity of such symptoms is determined by the degree of anemia, the rate at which it manifests, and any existing comorbidities.
The symptoms range from mild to severe, including dizziness, palpitation, dyspnea, anorexia, and difficulty concentrating. Fatigue, one of the most common Chemotherapy Induced Anemia symptoms in cancer patients, has a negative impact on their quality of life.
Chemotherapy Induced Anemia Epidemiology Segmentation
As per DelveInsight, the total Chemotherapy Induced Anemia incident cases were approx 1.6 million cases in the 7MM in 2021.
Among EU5 countries, Germany has the highest number of Chemotherapy Induced Anemia incident cases in 2021.
The Chemotherapy Induced Anemia Market Report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
- Incident Cases of Chemotherapy Induced Anemia
- Severity-specific Cases of Chemotherapy Induced Anemia
- Incidence of Chemotherapy Induced Anemia per chemo cycles
Know how the epidemiological trends are going to look like in 2032 for the 7MM by downloading @ Chemotherapy Induced Anemia Epidemiological Insights
Chemotherapy Induced Anemia Treatment Market
The two main goals of Chemotherapy Induced Anemia treatment are to relieve symptoms and improve quality of life. Failure to treat Chemotherapy Induced Anemia contributes to a suboptimal response to chemotherapy, and correcting anemia in patients is associated with improved chemotherapy responses. Packed red blood cell transfusions, erythropoietin stimulating agents (ESAs), and iron supplementation are currently used for Chemotherapy Induced Anemia treatment.
The goal of red blood cell transfusion is to maintain or improve the blood's capacity to carry oxygen so that oxygen can be delivered to tissues. Iron supplementation is an underutilized Chemotherapy Induced Anemia therapy that has traditionally been administered orally. Unlike the oral form, which is hampered by hepcidin, intravenous iron is directly absorbed by macrophages and is not hampered by a disrupted absorption system in an inflammatory setting.
Discover more about Chemotherapy Induced Anemia guidelines, marketed drugs, and the current treatment options at Chemotherapy Induced Anemia Treatment Guidelines
Chemotherapy Induced Anemia Pipeline Therapies and Key Companies
- Roxadustat: Astellas/FibroGen/AstraZeneca
- ALRN-6924: Aileron Therapeutics
- Desidustat: Zydus Cadila
Discover more about therapy set to grab substantial Chemotherapy Induced Anemia market share at Chemotherapy Induced Anemia Drugs
Chemotherapy Induced Anemia Market Dynamics
The increase in the number of cancer cases, the Chemotherapy Induced Anemia incidence is likely to rise in the coming years thereby increasing the need for Chemotherapy Induced Anemia treatment, which further increases the Chemotherapy Induced Anemia market size. The challenges in treating anemic patients have given rise to a novel class of agents – HIF-PH inhibitors that can change the existing anemia treatment paradigm. Moreover, with the availability of new IV iron supplementation, anemia has become more manageable and thus drives the Chemotherapy Induced Anemia market growth.
However, the diversity of patient presentation and symptomatology can act as a hurdle for Chemotherapy Induced Anemia market growth. In addition, significant undertreatment of Chemotherapy Induced Anemia, cost implications of the Chemotherapy Induced Anemia management can also limit the Chemotherapy Induced Anemia market growth.
Know more about which pharma player in the Chemotherapy Induced Anemia market is set to emerge as the trendsetter at Chemotherapy Induced Anemia Companies
Scope of the Chemotherapy Induced Anemia Market Report
- Study Period: 2019-2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Chemotherapy Induced Anemia Companies: Astellas, FibroGen, AstraZeneca, Aileron Therapeutics, Zydus Cadila, and others
- Key Pipeline Therapies: Roxadustat (FG-4592), ALRN-6924, Desidustat, and others
- Therapeutic Assessment: Chemotherapy Induced Anemia current marketed and emerging therapies
- Chemotherapy Induced Anemia Market Dynamics: Chemotherapy Induced Anemia market drivers and barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Chemotherapy Induced Anemia Market Access and Reimbursement
Discover more about the future Chemotherapy Induced Anemia market share of treatment therapies at Chemotherapy Induced Anemia Treatment Market
Table of Contents
1. | Key Insights |
2. | Report Introduction |
3. | Overview at a Glance |
4. | Executive Summary |
5. | Disease Background and Overview |
6. | Epidemiology and Patient Population |
7. | Patient Journey |
8. | Emerging Drugs |
9. | Other Assets |
10. | 7MM Chemotherapy Induced Anemia Market Analysis |
11. | Chemotherapy Induced Anemia Market Drivers |
12. | Chemotherapy Induced Anemia Market Barriers |
13. | KOL Views |
14. | SWOT |
15. | Unmet Needs |
16. | Appendix |
17. | DelveInsight Capabilities |
18. | Disclaimer |
19. | About DelveInsight |
Get in touch with our Business executive at Healthcare Due Diligence Services
Related Reports
Chemotherapy Induced Anemia Pipeline
Chemotherapy Induced Anemia Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Chemotherapy Induced Anemia companies involved such as Astellas, FibroGen, AstraZeneca, among others.
Chemotherapy Induced Anemia Epidemiology Forecast
Chemotherapy Induced Anemia Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical, and forecasted Chemotherapy Induced Anemia epidemiology in the 7MM.
Anemia Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Anemia companies such as Vifor, Renibus Therapeutics, Rockwell Medical Technologies, among others.
Anemia in Elderly Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Anemia in Elderly companies such as Stanford University, Vifor, among others.
Anemia in Chronic Kidney Disease Market
Anemia in Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Anemia in Chronic Kidney Disease companies such as Pieris Pharmaceuticals, Jiangsu HengRui Medicine, Shenyang Sunshine Pharmaceutical, Biocad, among others.
Aplastic Anemia Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Aplastic Anemia companies such as Pfizer, BioLineRx, Ltd., Regeneron Pharmaceuticals, Gamida Cell, among others.
Fibromyalgia Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Fibromyalgia companies such as Tonix Pharmaceuticals, Aptinyx, Virios Therapeutics, Inc., Teva Pharmaceuticals, Knop Laboratorios, among others.
Other Trending Blood-related Disorders Reports
Sickle Cell Disease Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Sickle Cell Disease companies such as CSL Behring, Magenta Therapeutics, Molecules for Health, Hillhurst Biopharmaceuticals, among others.
Hemophilia A Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Hemophilia A companies such as Hoffmann-La Roche, Chugai Pharmaceutical, Shire, Pfizer, among others.
Related Healthcare Blogs
Iron Deficiency Anemia Therapy Market
Warm Autoimmune Hemolytic Anemia Treatment
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
[email protected]
+1(919)321-6187
www.delveinsight.com
Connect With Us at: LinkedIn | Facebook | Twitter
SOURCE DelveInsight Business Research, LLP
Share this article